BrainsWay to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Summary

BrainsWay, a leader in non-invasive brain disorder treatments, announced that CEO Christopher von Jako will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 1:40 PM ET. The company specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which has received FDA approval for various disorders, including major depressive disorder in 2013, obsessive-compulsive disorder in 2018, and smoking addiction in 2020. BrainsWay is actively conducting clinical trials across multiple psychiatric and neurological conditions.

CRESSKILL, N.J. and JERUSALEM, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22 at 1:40 PM ET.

Presentation Details:                                                     

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date:	Tuesday, September 22, 2020
Time:	1:40pm Eastern Time

About BrainsWay

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit www.brainsway.com.

Contacts:
BrainsWay:
Judy Huber
SVP and Chief Financial Officer
Judy.huber@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com 

FAQ

What date will BrainsWay present at the Oppenheimer Summit?

BrainsWay will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020.

What time is BrainsWay's presentation at the Oppenheimer Summit?

BrainsWay's presentation is scheduled for 1:40 PM ET.

Who will represent BrainsWay at the Oppenheimer Summit?

Christopher von Jako, Ph.D., the President and CEO of BrainsWay, will present.

What technology does BrainsWay specialize in?

BrainsWay specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) technology.

What FDA approvals has BrainsWay received?

BrainsWay has received FDA approval for treatments of major depressive disorder in 2013, obsessive-compulsive disorder in 2018, and smoking addiction in 2020.

Is BrainsWay conducting any clinical trials?

Yes, BrainsWay is conducting clinical trials for various psychiatric and neurological disorders.